DelveInsight’s “Dry Eye Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Dry Eye Disease pipeline landscapes. It comprises Dry Eye Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Dry Eye Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Dry Eye Disease pipeline products.
Some of the key takeaways of the Dry Eye Disease Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Oyster Point Pharma, Ocugen, HanAll Biopharma, mc2 therapeutics, Novartis, Aurinia Pharmaceuticals, Kala Pharmaceuticals, etc., are developing therapies for the treatment of Dry Eye Disease.
-
Emerging therapies such as OC-01/OC-02, OCU 310, HMB9036, MC2-03, ECF843, Voclosporin ophthalmic solution, KPI-121, are expected to have a significant impact on the Dry Eye Disease market in the coming years.
-
Recent advances within the understanding of tear film physiology and pathology have allowed the formulation of a spread of tear substitutes capable of addressing specific deficiencies of tear components.
Get an overview of pipeline landscape @ Dry Eye Disease Clinical Trials Analysis
Dry eye disease is a common condition that happens when your tears aren’t able to provide adequate lubrication for your eyes. Tears are often inadequate and unstable for several reasons. For instance, dry eyes may occur if you do not produce enough tears or if you produce poor-quality tears.
Dry Eye Disease Emerging Drugs
-
OC-01/OC-02 by Oyster Point Pharma
-
OCU 310 by Ocugen
-
HMB9036 by HanAll Biopharma
-
MC2-03 by mc2 therapeutics
-
ECF843 by Novartis
-
Voclosporin ophthalmic solution by Aurinia Pharmaceuticals
-
KPI-121 by Kala Pharmaceuticals
-
And others.
Scope of Dry Eye Disease Pipeline Drug Insight
-
Coverage: Global
-
Major Players:Oyster Point Pharma, Ocugen, HanAll Biopharma, mc2 therapeutics, Novartis, Aurinia Pharmaceuticals, Kala Pharmaceuticals, and others.
-
Pipeline Therapies: OC-01/OC-02, OCU 310, HMB9036, MC2-03, ECF843, Voclosporin ophthalmic solution, KPI-121, and others.
Table of Contents
|
1 |
Dry Eye Disease Report Introduction |
|
2 |
Dry Eye Disease Executive Summary |
|
3 |
Dry Eye Disease Overview |
|
4 |
Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Dry Eye Disease Pipeline Therapeutics |
|
6 |
Dry Eye Disease Late Stage Products (Phase II/III) |
|
7 |
Dry Eye Disease Mid Stage Products (Phase II) |
|
8 |
Dry Eye Disease Early Stage Products (Phase I) |
|
9 |
Dry Eye Disease Preclinical Stage Products |
|
10 |
Dry Eye Disease Therapeutics Assessment |
|
11 |
Dry Eye Disease Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Dry Eye Disease Key Companies |
|
14 |
Dry Eye Disease Key Products |
|
15 |
Dry Eye Disease Unmet Needs |
|
16 |
Dry Eye Disease Market Drivers and Barriers |
|
17 |
Dry Eye Disease Future Perspectives and Conclusion |
|
18 |
Dry Eye Disease Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Dry Eye Disease Drugs Pipeline Report
Related Reports:
Dry Eye Disease Epidemiology
DelveInsight’s ‘ Dry Eye Disease- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Dry Eye Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/